Business
SAREUM HOLDINGS PLC : Selection for Preclinical...
SAREUM HOLDINGS PLC : Selection for Preclinical....
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n SAREUM HOLDINGS PLC : Selection for Preclinical Candidate(AIM: SAR)15 July 2013SAREUM HOLDINGS PLC (\"Sareum\")Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor ProgrammeSareum, the specialist cancer drug discovery business, is pleased to announce the selection of a preclinical development candidate from their Aurora+FLT3 kinase programme, which targets Acute Myeloid Leukaemia (AML).As reported in February 2013, recent studies carried out by Sareum sought to differentiate the two most promising programme compounds. Whilst both molecules demonstrate similar efficacy in disease models, the preclinical candidate shows clear benefits in safety models and predicted human exposure, based on a number of in vitro assays.The focus of the programme remains the treatment of AML, but both compounds also demonstrated potent cell-killing activity against other cancers, particularly Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma and Anaplastic Large-Cell Lymphoma. Further investigation of the candidate in additional disease models will be carried out during preclinical development.Sareum's CEO, Dr Tim Mitchell, commented: \"The selection of a preclinical development candidate is a major milestone for the programme that will significantly enhance the licensing package. Our research indicates that the performance in model systems and potential for once-daily dosing of this candidate are likely to give it a competitive advantage.\"For further information:Sareum Holdings plcTim Mitchell01223 497 700Sanlam Securities UK (Nomad)Simon Clements020 7628 2200Hybridan LLP (Broker)Claire Noyce, William Lynne020 7947 4350 / 020 7947 4361The Communications Portfolio Limited (Media enquiries)Ariane [email protected] 7536 2028Notes for editors: About Sareum Holdings plcSareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the colla...